Atara Biotherapeutics Inc expected to post a loss of 46 cents a share - Earnings Preview

Atara Biotherapeutics

08/08/2025 12:29

Atara Biotherapeutics Inc ATRA.OQ ATRA.O is expected to  show a fall in quarterly revenue when it reports  results on August 11 (estimated) for the period ending June 30 2025

The Thousand Oaks California-based  company is expected to report a 80.6% decrease in revenue to $5.567 million from $28.64 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Atara Biotherapeutics Inc is for a loss of 46 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Atara Biotherapeutics Inc is $17.00, about 35.5% above its last closing price of $10.96

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-1.96
-1.98
3.50
Beat
276.8
Dec. 31 2025
-3.76
-3.58
-1.19
Beat
66.7
Sep. 30 2024
-2.11
-1.93
-2.93
Missed
-51.6​
Jun. 30 2024
-1.38
-1.56
-3.10
Missed
-98.4
​​Mar. 31 2024
-6.17
-6.41
-5.75
Beat
10.3
Dec. 31 2023
-7.75
-12.05
-14.00
Missed
-16.2​
Sep. 30 2023
-16.57
-16.55
-16.50
Beat
0.3
Jun. 30 2023
-16.58
-16.81
-17.00
Missed
-1.1

This summary was machine generated August 8 at 11:29 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)